Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 4/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12698414 | 1.00 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2HSD17B10SIRT2 | |
| SCHEMBL7156373 | 1.00 | ALDH1A1 (0.58) | ALDH1A1TSHRSMN1; SMN2HSD17B10SIRT2 | |
| SCHEMBL880444 | 0.87 | TP53 (0.59) | ALDH1A1TSHRSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL880264 | 0.83 | LMNA (0.67) | ALDH1A1KMT2ATDP1L3MBTL1MEN1 | |
| SCHEMBL30005837 | 0.83 | LMNA (0.67) | ALDH1A1KMT2ATDP1L3MBTL1MEN1 | |
| SCHEMBL3053841 | 0.83 | DDB1 (0.65) | ALDH1A1TSHRSMN1; SMN2HSD17B10DDB1 | |
| SCHEMBL12559670 | 0.81 | TDP1 (0.57) | ALDH1A1TSHRSMN1; SMN2SIRT2KMT2A | |
| SCHEMBL880446 | 0.81 | KMT2A (0.48) | TSHRSMN1; SMN2SIRT2BRD4CREBBP | |
| SCHEMBL14094474 | 0.81 | SIRT2 (0.66) | ALDH1A1TSHRHSD17B10SIRT2KMT2A | |
| SCHEMBL880497 | 0.80 | KMT2A (0.53) | ALDH1A1TSHRSMN1; SMN2KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109836383-B | Method for preparing 3, 4-dihydroquinoline-2 (1H) -ketone compound | 安徽理工大学 | 2022-04-19 | — | — | CN | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2016-02-25 | — | — | US | disclosed |
| US-9212209-B2 | Screening methods for spinal muscular atrophy | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-15 | — | — | US | disclosed |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | THE UNIVERSITY OF MASSACHUSETTS | 2014-07-10 | — | — | US | disclosed |
| US-8440705-B2 | 2,3,4,7,8,9-hexahydro-1H-cyclopenta[h]quinolin-2-one or 2,3,4,6,7,8-hexahydro-1H-cyclopenta[g]quinolin-2-one; Alzheimer's disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2433634-A2 | Compounds, compositions and methods of inhibiting a-synuclein toxicity | The Whitehead Institute for Biomedical Research (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-10-23 | — | — | US | disclosed |
| US-7390801-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ATHENA NEUROSCIENCES, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0951466-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS | Elan Pharmaceuticals, Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5968952-A | ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-10-19 | — | — | US | disclosed |
| CN-1200732-A | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1998-12-02 | — | — | CN | disclosed |
| WO-1998038177-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR INHIBITING β-AMYLOID PEPTIDE | ELAN PHARMACEUTICALS, INC. (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998028268-A2 | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| WO-1997016443-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |
| EP-0382687-B1 | Benzofused-N-containing heterocycle derivatives | BOEHRINGER INGELHEIM ITALIA (IT) | 1995-12-27 | — | — | EP | disclosed |
| US-5106851-A | Respiratory system disorders | ISTITUTO DE ANGELI S.P.A. (IT) | 1992-04-21 | — | — | US | disclosed |
| EP-0382687-A2 | Benzofused-N-containing heterocycle derivatives | BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261953-A1 | Compounds, Compositions and Methods of Inhibiting Alpha-Synuclein Toxicity | SNCA, PARK7, HTT | ALDH1A1 171/4885TSHR 3894/4885SMN1; SMN2 41/4885 |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | CTTN, PTK2, CDC42 | ALDH1A1 4856/4885TSHR 4226/4885SMN1; SMN2 1411/4885 |
| US-20160052935-A1 | COMPOUNDS FOR USE IN SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, MTPN | ALDH1A1 1231/4885TSHR 4716/4885SMN1; SMN2 1/4885 |
| US-20140193906-A1 | SCREENING METHODS FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MYOF, MTPN | ALDH1A1 1386/4885TSHR 4677/4885SMN1; SMN2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.